Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial
Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial
About this item
Full title
Author / Creator
Publisher
United States: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
United States: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Systemic treatment of metastatic adrenocortical carcinoma (ACC) remains limited to chemotherapy and mitotane. Preliminary evidence suggesting that antitumor immune responses can be elicited in ACC has fostered interest in checkpoint inhibitors such as anti-PD-1 nivolumab.
The primary endpoint was objective response rate according to the response...
Alternative Titles
Full title
Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2253299614
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2253299614
Other Identifiers
ISSN
0021-972X
E-ISSN
1945-7197
DOI
10.1210/jc.2019-00600
